MX2019005102A - Poxvirus quimericos sinteticos. - Google Patents

Poxvirus quimericos sinteticos.

Info

Publication number
MX2019005102A
MX2019005102A MX2019005102A MX2019005102A MX2019005102A MX 2019005102 A MX2019005102 A MX 2019005102A MX 2019005102 A MX2019005102 A MX 2019005102A MX 2019005102 A MX2019005102 A MX 2019005102A MX 2019005102 A MX2019005102 A MX 2019005102A
Authority
MX
Mexico
Prior art keywords
synthetic chimeric
chimeric poxviruses
poxviruses
synthetic
viruses
Prior art date
Application number
MX2019005102A
Other languages
English (en)
Spanish (es)
Inventor
Lederman Seth
Evans David
Noyce Ryan
Original Assignee
Evans David
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evans David filed Critical Evans David
Publication of MX2019005102A publication Critical patent/MX2019005102A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2019005102A 2016-11-02 2017-11-02 Poxvirus quimericos sinteticos. MX2019005102A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662416577P 2016-11-02 2016-11-02
US201662434794P 2016-12-15 2016-12-15
PCT/US2017/059782 WO2018085582A1 (en) 2016-11-02 2017-11-02 Synthetic chimeric poxviruses

Publications (1)

Publication Number Publication Date
MX2019005102A true MX2019005102A (es) 2019-10-30

Family

ID=62075555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005102A MX2019005102A (es) 2016-11-02 2017-11-02 Poxvirus quimericos sinteticos.

Country Status (12)

Country Link
US (4) US11345896B2 (enExample)
EP (1) EP3535389A4 (enExample)
JP (3) JP2019535311A (enExample)
CN (1) CN110431228B (enExample)
AU (2) AU2017353868C1 (enExample)
CA (1) CA3042694A1 (enExample)
IL (2) IL319942A (enExample)
MX (1) MX2019005102A (enExample)
SG (1) SG11201903893PA (enExample)
TW (2) TWI887191B (enExample)
WO (1) WO2018085582A1 (enExample)
ZA (3) ZA201902868B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319942A (en) 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
WO2018148710A1 (en) * 2017-02-13 2018-08-16 Excision Biotherapeutics, Inc. Visualizing viral reservoirs and dissemination in vivo
CA3099330A1 (en) * 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
US20240024393A1 (en) * 2019-01-25 2024-01-25 Virocure, Inc. Pharmaceutical composition for preventing or treating cancer, comprising squirrel fibroma virus and reovirus
US20230097513A1 (en) * 2020-02-03 2023-03-30 City Of Hope Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
BR112022016992A2 (pt) * 2020-02-26 2022-10-25 Tonix Pharma Ltd Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
EP4153228A4 (en) 2020-05-17 2024-07-10 City of Hope CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS
BR112023015467A2 (pt) 2021-02-02 2023-10-10 Geovax Inc Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica
WO2023168286A1 (en) 2022-03-01 2023-09-07 Tonix Pharmaceuticals Holding Corp. Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof
CN117264909B (zh) * 2023-10-25 2024-11-26 深圳湾实验室 反式互补缺陷猴痘病毒及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2787577A (en) 1953-12-01 1957-04-02 Lilly Co Eli Stable smallpox vaccine
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US6723325B1 (en) 2001-04-23 2004-04-20 Acambis, Inc. Smallpox vaccine
CA2431349A1 (en) * 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
EP1678292A4 (en) 2003-09-18 2008-05-07 Univ Emory IMPROVED MVA VACCINES
WO2006022215A1 (ja) 2004-08-23 2006-03-02 The Japan Health Sciences Foundation SARS-コロナウイルスタンパク質をコードするDNAを保有する組換えワクチニアウイルスDIs株、およびその利用
CN101020055B (zh) 2006-02-16 2012-08-08 中国疾病预防控制中心性病艾滋病预防控制中心 基于复制型痘苗病毒载体的sars疫苗
EP2415783B1 (en) 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
WO2009117030A2 (en) * 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
FI20115914L (fi) 2011-09-16 2013-03-17 Oncos Therapeutics Ltd Muunnettu onkolyyttinen virus
WO2014160475A1 (en) 2013-03-13 2014-10-02 Aboody Karen S Tropic cell based virotherapy for the treatment of cancer
CA2909225C (en) 2013-04-10 2019-06-18 Tot Shanghai R&D Center Co., Ltd. Mutant vaccinia virus strains, uses thereof and method of producing the same
EP3045181B1 (en) 2015-01-19 2018-11-14 Ludwig-Maximilians-Universität München A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV)
HK1248588A1 (zh) 2015-08-11 2018-10-19 Calidi Biotherapeutics, Inc. 用於癌症治疗中的天花疫苗
JP2019528753A (ja) 2016-09-21 2019-10-17 スティーブン エイチ. ソーン, 高移動度グループboxi突然変異体
IL319942A (en) 2016-11-02 2025-05-01 Evans David Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof
ES2702618B2 (es) 2017-09-04 2019-10-31 Inst De Salud Carlos Iii Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica.
CA3099330A1 (en) 2018-05-02 2019-11-07 Tonix Pharma Holdings Limited Synthetic chimeric vaccinia virus
US20210236619A1 (en) 2018-05-02 2021-08-05 Tonix Pharma Holdings Limited Stem cells comprising synthetic chimeric vaccinia virus and methods of using them

Also Published As

Publication number Publication date
CA3042694A1 (en) 2018-05-11
SG11201903893PA (en) 2019-05-30
AU2024200997A1 (en) 2024-03-07
US12365879B2 (en) 2025-07-22
EP3535389A4 (en) 2020-06-03
US20230002741A1 (en) 2023-01-05
AU2017353868A1 (en) 2019-05-16
TW202528334A (zh) 2025-07-16
JP2024107257A (ja) 2024-08-08
AU2017353868C1 (en) 2024-06-06
US20260022350A1 (en) 2026-01-22
JP2022164900A (ja) 2022-10-27
ZA202403393B (en) 2025-08-27
IL319942A (en) 2025-05-01
CN110431228A (zh) 2019-11-08
CN110431228B (zh) 2024-04-02
IL266399B2 (en) 2025-09-01
ZA201902868B (en) 2022-12-21
BR112019008781A2 (pt) 2019-07-16
WO2018085582A1 (en) 2018-05-11
ZA202204981B (en) 2024-09-25
EP3535389A1 (en) 2019-09-11
IL266399B1 (en) 2025-05-01
JP2019535311A (ja) 2019-12-12
US20180251736A1 (en) 2018-09-06
NZ752893A (en) 2025-10-31
IL266399A (en) 2019-06-30
US11345896B2 (en) 2022-05-31
TW201819400A (zh) 2018-06-01
TWI887191B (zh) 2025-06-21
AU2017353868B2 (en) 2024-02-29
US20260139233A1 (en) 2026-05-21

Similar Documents

Publication Publication Date Title
ZA202403393B (en) Synthetic chimeric poxviruses
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
MX2020011586A (es) Virus vaccinia quimerico sintetico.
EA201890817A1 (ru) Кристаллические формы бета-никотинамида мононуклеотида
EA201691945A1 (ru) Антитела к гемагглютинину вируса гриппа типа b и способы их применения
MX2018014154A (es) Polinucleotidos moduladores.
MX390014B (es) Compuestos de dinucleótidos cíclicos y métodos de uso.
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
MX387421B (es) Producción de virus en huevos aviares.
EP3720487A4 (en) DENGUE VIRUS VACCINE COMPOSITION FORMULATIONS
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
EP3939604A3 (en) Influenza hemagglutinin protein vaccines
MX379510B (es) Coronavirus bovino atenuado y vacunas relacionadas.
HUE055282T2 (hu) TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
EP3368547A4 (en) CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS AND METHOD FOR USE THEREOF
MY192739A (en) Vaccine compositions against dengue virus diseases
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2019007924A (es) Vacunas contra la influenza.
EA201991319A1 (ru) Вакцины аттенуированного свиного гриппа и способы их изготовления и применения